Autonomix Medical Strengthens Patent Protection for Platform Technology Enabling Precision Access, Treatment Delivery and Procedural Validation
Globe Newswire•02/10/2026•08:05 ET
0
Key Highlights
- ➤Canadian Patent No. 3,183,802 issued to Autonomix Medical (AMIX)
- ➤Global intellectual property portfolio now includes 112 issued or pending patent applications
- ➤Patent protects catheter-based transvascular access, treatment guidance, and real-time validation
- ➤Related patents previously issued in the United States and Europe
Expert Statements
Brad Hauser, Chief Executive Officer of Autonomix Medical
“We believe the future of nerve-targeted therapy lies not only in identifying the appropriate neural target, but in enabling physicians to precisely access that target, deliver therapy with objective physiological feedback, and determine whether the intended therapeutic effect has been achieved.”
Brad Hauser, Chief Executive Officer of Autonomix Medical
“This patent strengthens protection around the core technologies that enable catheter-based transvascular intervention, reinforcing the differentiated capabilities of our platform and supporting our long-term strategy to advance next-generation neuromodulation technologies across multiple clinical applications.”
Patent expands protection for catheter-based technologies enabling transvascular access, treatment guidance, adaptive treatment delivery, and real-time procedural validation beyond the lumen wall
Patent reinforces Autonomix’s transvascular intervention platform across multiple nerve-targeted therapies
Get started
Create a free account to read the full story.